Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Recruiting · NCT07322783 · Registry updated 2026-01-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification | EGFR Positive Non-small Cell Lung Cancer; MET Amplification | Recruiting | Phase 2 | 2026-01-07 | NCT07322783 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Qingdao Central Hospital | 10 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Qingdao Central Hospital | Qingdao | China | 3 |